ABSI — Absci Corporation stock price, charts and financials

Latest market price

8.48

+0.55+6.94%

Overview Short InterestFilings

ABSIQT61Absci Corporation·NASDAQ

Overview Short InterestFilings

8.48+6.94%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.94	Insider Own	30.44%	Shs Outstand	169.40M	Perf Week	18.93%

Market Cap	1.44B	Forward P/E	-	EPS next Y	-0.70	Insider Trans	0.44%	Shs Float	146.89M	Perf Month	-26.52%

Enterprise Value	1.31B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	24.34%	Perf Quarter	50.89%

Income	-113.00M	P/S	-	EPS this Y	20.42%	Inst Trans	-	Short Ratio	5.95	Perf Half Y	180.79%

Sales	5.00M	P/B	8.35	EPS next Y	6.56%	ROA	-60.55%	Short Interest	35.75M	Perf YTD	142.98%

Book/sh	1.02	P/C	11.40	EPS next 5Y	-	ROE	-63.58%	52W High	12.06 -29.68%	Perf Year	192.41%

Cash/sh	0.74	P/FCF	-	EPS past 3/5Y	-	ROIC	-72.28%	52W Low	2.24 278.57%	Perf 3Y	298.12%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-20.63% -9.71%	Gross Margin	-1316.88%	Volatility	8.06% 7.76%	Perf 5Y	-63.45%

Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	0.00%	Oper. Margin	-7000.82%	ATR (14)	0.75	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	6.59	Sales Y/Y TTM	0.00%	Profit Margin	-6450.76%	RSI (14)	51.00	Recom	2.38

Dividend Gr. 3/5Y	-	Current Ratio	6.59	EPS Q/Q	9.52%	SMA20	-2.34%	Beta	2.37	Target Price	12.40

Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	2.90%	Rel Volume	0.36	Prev Close	7.93

Employees	140	LT Debt/Eq	0.02	Earnings	Aug 11	SMA200	81.13%	Avg Volume	5.48M	Price	8.48

IPO Date	Jul 22, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.48% -82.89%	Net Debt/EBITDA	0.04	Volume	1,982,373	Change	6.94%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-25-26	Reiterated	Morgan Stanley	Overweight	$4.10 → $10
Jun-25-26	Reiterated	HC Wainwright & Co.	Buy	$8.00 → $16
Jun-15-26	Reiterated	Guggenheim	Buy	$15
Jun-04-26	Initiated	Leerink	Outperform	$12
May-28-26	Initiated	BTIG	Buy	$9.00
May-14-26	Reiterated	Morgan Stanley	Overweight	$4.20 → $4.10
Jan-08-26	Reiterated	Morgan Stanley	Overweight	$4.32
Mar-21-24	Reiterated	Stifel Nicolaus		$6.00
Aug-12-22	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-22	Upgrade	Cowen & Co.	Market Perform → Outperform

Latest News

Jul-30-26

Jul-30-2610:41AM

Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?zacks.com

Jul-24-26

Jul-24-2610:00AM

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headedgurufocus.com

Jul-14-26

Jul-14-2604:05PM

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026globenewswire.com

Jul-13-26

Jul-13-2610:55AM

Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Knowzacks.com

Jul-02-26

Jul-02-2601:01PM

Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buyzacks.com

08:32AM

Truist Securities Maintains Buy on Absci, Raises Price Target to $17Benzinga

Jun-26-26

Jun-26-2610:27AM

Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapyYahoo

08:06AM

Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?Yahoo

Jun-25-26

Jun-25-2602:21PM

ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss StudyYahoo

10:18AM

ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?Yahoo

09:06AM

Micron To Rally More Than 57%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga

08:07AM

HC Wainwright & Co. Maintains Buy on Absci, Raises Price Target to $16Benzinga

03:24AM

Why Did UAL, GLW, ABSI Stocks Surge To 52-Week Highs Today?Yahoo

Jun-24-26

Jun-24-2607:55PM

ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed RaiseYahoo

07:00PM

Keep an eye on the top gainers and losers in Wednesday's session.ChartMill

Company

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	5	3	5	6	6	5	5	2
Cost of Goods Sold Incl. D&A	56	12	62	48	59	45	11	0
Gross Profit	-53	-9	-58	-42	-53	-40	-7	2
Selling, General and Administrative Excl. Other	9	35	0	0	0	0	6	4
Research and Development	72	81	64	48	59	45	11	4
Other Operating Expense	-16	0	-13	26	-5	-10	-10	0
Operating Income	-118	-125	-109	-116	-107	-75	-13	-6
Interest Expense	0	0	1	1	1	3	1	0
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	5	10	6	6	2	-31	0	0
Net Income Before Taxes	-112	-115	-103	-110	-105	-110	-14	-7
Income Taxes	0	0	0	0	0	-9	0	0
Consolidated Net Income	-113	-115	-103	-111	-105	-101	-14	-7
Net Income From Continuing Operations	-113	-115	-103	-111	-105	-101	-14	-7
Net Income	-113	-115	-103	-111	-105	-101	-14	-7
EPS (Recurring)	-0.94	-0.84	-0.94	-1.20	-1.15	-1.11	-0.54	-0.07
EPS (Basic, Before Extraordinaries)	-0.94	-0.84	-0.94	-1.20	-1.15	-1.11	-0.54	-0.07
EPS (Diluted)	-0.94	-0.84	-0.94	-1.20	-1.15	-1.11	-0.54	-0.07
EBITDA	-99	-103	-94	-80	-91	-68	-13	-6
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	217.09	159.38	57.64	64.40	31.85	152.52	—	—
Gross Margin	-1,060.00	-300.00	-1,160.00	-700.00	-883.33	-800.00	-140.00	100.00
Operating Margin	-2,360.00	-4,166.67	-2,180.00	-1,933.33	-1,783.33	-1,500.00	-260.00	-300.00
Net Margin	-2,260.00	-3,833.33	-2,060.00	-1,850.00	-1,750.00	-2,020.00	-280.00	-350.00
Shares Outstanding	128	137	110	92	91	93	92	92
Market Capitalization	1,085	478	288	386	191	763	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Szela Mary T	Director	Jun 30 '26	Buy	11.54	12,900	148,866	21,300	Jul 06
Pangalos Menelas N	Director	May 13 '26	Buy	5.36	37,453	200,748	232,308	May 13
Busch Andreas	Chief Innovation Officer	Mar 12 '26	Buy	2.29	100,000	229,000	421,446	Mar 16
Pangalos Menelas N	Director	Feb 27 '26	Buy	2.74	75,095	205,760	189,055	Mar 03
McClain Sean	Chief Executive Officer	Feb 23 '26	Option Exercise	1.21	396,399	479,643	8,730,966	Feb 25
McClain Sean	Chief Executive Officer	Feb 02 '26	Sale	2.99	26,761	80,015	8,334,567	Feb 04
Jonasson Zachariah	CFO / CBO	Feb 02 '26	Sale	2.99	17,496	52,313	383,538	Feb 04
VAN HOUTEN FRANS	Director	Dec 05 '25	Buy	3.72	40,000	148,800	63,320	Dec 09
Bedrick Todd	SVP, CAO	Sep 22 '25	Buy	2.70	10,000	27,000	180,428	Sep 24
Pangalos Menelas N	Director	Sep 22 '25	Buy	2.66	95,785	254,788	113,960	Sep 24
Busch Andreas	Chief Innovation Officer	Jul 28 '25	Buy	3.04	50,000	152,000	327,264	Jul 29
Jonasson Zachariah	CFO / CBO	Jun 13 '24	Sale	4.98	19,859	98,892	384,751	Jun 14
Jonasson Zachariah	CFO / CBO	Jun 13 '24	Option Exercise	3.39	28,700	97,293	404,610	Jun 14
Phoenix Venture Partners II LP	10% Owner	May 22 '24	Sale	4.40	3,100,000	13,640,000	11,279,522	May 28
Redmile Group, LLC	Director	Mar 01 '24	Buy	4.50	222,222	999,999	8,253,316	Mar 05

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.